there seems to be some heavy resistance around these level with a lot of potential upside.

Anyone recommend a good price to get in? Looking very tempting at these levels.

3rd Quarter Results

Summary
· Group turnover £5.6 billion, -3% excluding divestments

- Pharmaceutical and Vaccines sales -3% with strong growth in Emerging Markets, +12%, Japan +6%, ViiV Healthcare +18%, offset by US -10%, and Europe -2%

- Respiratory -8% reflecting significant changes to pricing and volumes for Advair in US; portfolio transition continues with total global respiratory sales expected to return to growth in 2016

- Q3 Consumer Healthcare sales -3%; recovery from supply interruptions on track with full year sales expected to be broadly flat subject to continued progress of supply recovery plan

· Targeted cost reductions and financial efficiencies help deliver Q3 core EPS of 27.9p +5% at CER and excluding divestments

· Continue to expect full year 2014 core EPS to be broadly similar to 2013 (at CER and on ex-divestment basis)

· Proposed 3-part transaction with Novartis on track for completion in H1 2015

- Will significantly strengthen Vaccines and Consumer Healthcare

- New balance for Group across core businesses of Pharmaceuticals, Vaccines and Consumer Healthcare

- Provides greater ability to create and deliver value for shareholders across the Group

· ViiV Healthcare: intention to explore an IPO of a minority shareholding to enhance future strategic flexibility and visibility within the Group

· New restructuring programme to refocus global pharmaceuticals business and cost base following divestment of oncology products and changed US respiratory market dynamics

- Approximately £1 billion annual cost savings to be delivered over 3 years with ~50% expected in 2016. Savings incremental to the existing announced programmes and additional to the benefits expected from the transaction

· R&D pipeline expected to fuel growth of pharmaceuticals business with sustained flow of new products over next 5-10 years

- Multiple phase II/III assets with significant potential, including: mepolizumab (severe asthma), sirukumab (RA), cabotegravir (HIV); losmapimod (ACS); ICS/LAMA/LABA (COPD); '863 (anaemia); '273 (ADA-SCID)

- Early clinical development opportunities include first-in-class molecules in epigenetics targeting oncology and immuno-inflammation (BETi, EZH2 and LSD-1); respiratory (PI3Kδ); cardiovascular diseases (TRPV4) and inflammatory diseases (RIP-1 & 2 kinases)

· Q3 dividend maintained at 19p per share

· FY14 dividend expected to be 80p +3%. 2015 dividend expected to be maintained at same level as 2014 with additional planned return of £4 billion to shareholders via a B-share scheme post completion of transaction

Some encouraging signs in today's statement imo.

Oct 22; Panmure Gordon: Hold - TP: down to 1425p from 1600 on 30 Sept.

This being a core high yield holding for me, I tend to look at low sp as an opportunity to add
and think recent sp under 1330, often well under that, was favourable, if holding for the long term.

#GlaxoSmithKline advises that its #ebola vaccine should be ready by the close of the year.

Ebola vaccine schedule

GSK news

https://www.ig.com/uk/market-insight-videos?bctid=3852337986001&bclid=3671160850001

Worth a quick listen for those interested in GSK.

Oct 23:
Barclays: Overweight - TP: 1600p
Deutsche: Hold - TP: 1390p (down from 1420)
JP Morgan: Neutral - TP N/A

Oct 24: Liberum Capital: Sell - TP: 1350p.

Not seen a sell note for GSK and such a low TP for a while.

Oct 28: Jefferies: Hold - TP: 1350p

Nov 7; Berenberg: Hold - TP: 1540p (down from 15755p).

NOv 21:

Liberum Capital reiterates: Sell - TP: 1350p
r
Although sp on the up lately, quite a few forecasts with low TPs..

Novartis vote on 18 December

Nov 25:
Exane BNP Parisbas: Underperform - TP 1330p

Dec 3: Morgan Stanley; Overweight - TP: 1700p retained.

Dec 9:
Bank of America: Underperform - TP: 1450p
JP Morgan: Neutral - TP: 1350p

Jan 5: JP Morgan: Underweight - New TP: 1300p (down from 1350p)

Jan 15:

Deutsche Bank: Hold - TP: 1300p
Jefferies: Hold - TP: 1350p

Jan 21: Credit Suisse: Underperform - TP: 1330p

Jan 23: Berenberg: Hold - TP: 1620p